Novo Nordisk Shares Plummet Amid Price Pressure Forecast

The Danish pharmaceutical company Novo Nordisk has seen its shares decline by nearly 50 per cent over the past year, following a warning of a significant drop in profits and sales for 2026. The firm, best known for its weight-loss drugs Wegovy and Ozempic, is now grappling with unprecedented pricing pressures that could see profits fall by as much as 13 per cent this year.

Mike Doustdar, the newly appointed chief executive, outlined the challenges facing the company during a recent press engagement. He highlighted a combination of factors that include a deal with the Trump administration aimed at reducing healthcare costs, increased competition—especially from Eli Lilly—and the impending expiration of patents for semaglutide, the active ingredient in Wegovy and Ozempic. Doustdar conveyed that these elements would dampen their previously robust growth in the obesity drug market.

Despite these challenges, he expressed optimism about the company’s long-term prospects. Novo Nordisk has launched a new pill version of Wegovy, which received regulatory approval in the United States in December. Initial reports suggest that the launch has attracted over 170,000 new patients within the first four weeks, indicating potential market expansion.

However, analysts are sceptical about the company’s guidance. Barclays analysts suggest that expectations for recovery may be overly optimistic, given that past predictions have not materialised as anticipated. The sharp decline in shares by 17.6 per cent on a recent trading day further underscores investor anxiety and the financial uncertainties ahead for Novo Nordisk.

As the pharmaceutical industry continues to evolve, Novo Nordisk finds itself at a critical juncture, needing to navigate a landscape marked by intense competitive pressures and market instability. Its ability to adapt and innovate will be crucial in securing its position as a leader in the weight-loss sector.